ceutical treatment or evaluating the need for 
such treatment to a bona fide current patient; 
‘‘(B) any local, State, or Federal law en-
forcement, narcotics control, licensure, discipli-
nary, or program authority, who certifies, under 
the procedures determined by the State, that 
the requested information is related to an indi-
vidual investigation or proceeding involving the 
unlawful diversion or misuse of a schedule II, 
III, or IV substance, and such information will 
further the purpose of the investigation or as-
sist in the proceeding; 
‘‘(C) the controlled substance monitoring 
program of another State or group of States 
with whom the State has established an inter-
operability agreement; 
‘‘(D) any agent of the Department of 
Health and Human Services, a State medicaid 
program, a State health department, or the 
Drug Enforcement Administration who certifies 
that the requested information is necessary for 
research to be conducted by such department, 
program, or administration, respectively, and 
the intended purpose of the research is related 
to a function committed to such department,
program, or administration by law that is not 
investigative in nature; or 
‘‘(E) an agent of the State agency or enti-
ty of another State that is responsible for the 
establishment and maintenance of that State’s 
controlled substance monitoring program, who 
certifies that— 
‘‘(i) the State has an application ap-
proved under this section; and 
‘‘(ii) the requested information is for 
the purpose of implementing the State’s 
controlled substance monitoring program 
under this section. 
‘‘(2) DRUG DIVERSION.—A State that elects to 
exercise its authority to notify the appropriate au-
thorities responsible for drug diversion investigations 
if information in the database maintained by the 
State under subsection (e) is suggestive of an unlaw-
ful diversion or misuse of a controlled substance, is 
encouraged to develop any such notification program 
in consultation with representatives of the medical 
community, including physicians and pharmacists or 
other interested stakeholders.
‘‘(g) LIMITATIONS.—In implementing or improving a 
controlled substance monitoring program under this sec-
tion, a State— 
‘‘(1) shall make reasonable efforts to limit the 
information provided pursuant to a valid request 
under subsection (f)(1) to the minimum necessary to 
accomplish the intended purpose of the request; and 
‘‘(2) shall limit information provided in re-
sponse to a request under subsection (f)(1)(D) to in-
formation provided in a form and manner that pre-
vents the identification of a provider or patient. 
‘‘(h) ELECTRONIC FORMAT.—The Secretary shall 
specify a uniform electronic format for the reporting, shar-
ing, and provision of information under this section. 
‘‘(i) RULES OF CONSTRUCTION.— 
‘‘(1) FUNCTIONS OTHERWISE AUTHORIZED BY 
LAW.—Nothing in this section shall be construed to 
restrict the ability of any authority, including any 
local, State, or Federal law enforcement, narcotics 
control, licensure, disciplinary, or program authority, 
to perform functions otherwise authorized by law. 
‘‘(2) NO PREEMPTION.—Nothing in this section 
shall be construed as preempting any State law, ex-
cept that no such law may relieve any person of a 
requirement otherwise applicable under this Act.